One of the key molecular alterations incorporated into the WHO Classifications of CNS Tumors in 2016 are mutations in IDH enzymes, which were originally discovered in 2006 in colorectal cancer and reported in gliomas in 2008 [3, 19, 20]. This evidence concerns the gene IDH2 and glioma.